for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Affimed NV

AFMD.OQ

Latest Trade

2.27USD

Change

-0.07(-2.99%)

Volume

169,248

Today's Range

2.21

 - 

2.37

52 Week Range

2.21

 - 

5.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Affimed Posts Q3 Loss Per Share Of EUR 0.17

Nov 19 (Reuters) - Affimed NV <A28.F>::AFFIMED REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q3 LOSS PER SHARE EUR 0.17.Q3 REVENUE EUR 2.1 MILLION VERSUS EUR 300,000.Q3 EARNINGS PER SHARE VIEW EUR -0.16, REVENUE VIEW EUR 4.0 MILLION -- REFINITIV IBES DATA.

Affimed Announces Pricing Of Public Offering Of Common Shares

Nov 8 (Reuters) - Affimed NV <A28.F>::AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 12.0 MILLION COMMON SHARES PRICED AT $2.50PER SHARE.

Affimed Announces Proposed Public Offering Of Common Shares

Nov 7 (Reuters) - Affimed NV <A28.F>::AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.

Affimed NV Announces Submission Of Investigational New Drug Application To U.S. FDA To Initiate First-In-Human Phase 1/2A Study Of AFM24

Oct 15 (Reuters) - Affimed NV <A28.F>::AFFIMED NV - ANNOUNCED SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA TO INITIATE A FIRST-IN-HUMAN PHASE 1/2A STUDY OF AFM24.AFFIMED NV - REGISTRATION-DIRECTED PHASE 2 STUDY OF AFM13 ON TRACK TO START THIS QUARTER.AFFIMED - FDA CLEARS STUDY OF STABLE COMPLEX OF AFM13 PRE-MIXED WITH CBNK CELLS IN PATIENTS WITH RELAPSED/REFRACTORY CD30-POSITIVE LYMPHOID MALIGNANCIES.

Affimed NV Q2 Revenue EUR 4.0 Million Versus EUR 200,000

Aug 7 (Reuters) - Affimed NV <A28.F>::AFFIMED REPORTS SECOND QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS.Q2 LOSS PER SHARE EUR 0.17.Q2 REVENUE EUR 4.0 MILLION VERSUS EUR 200,000.

Affimed Announces Positive Clinical Data On AFM13 In CD30+ Lymphoma

June 24 (Reuters) - AFFIMED NV <A28.F>::ANNOUNCES CLINICAL DATA UPDATE ON LEAD PRODUCT CANDIDATE AFM13 IN CD30+ LYMPHOMA AT ICML 2019.COMBINATION OF AFM13 AND PEMBROLIZUMAB WAS WELL TOLERATED.DATA SUPPORT POTENTIAL OF AFM13 AS A NOVEL IMMUNO-THERAPEUTIC TO TREAT CD30-EXPRESSING LYMPHOMAS.REGISTRATION-DIRECTED PHASE 2 INTERNATIONAL MULTICENTER STUDY OF AFM13 IN REFRACTORY PERIPHERAL T CELL LYMPHOMA (PTCL) AND T-MF IS PLANNED.AFM13 WAS WELL TOLERATED AND RESULTED IN A HIGH ORR OF 50% (1 CR AND 4 PRS) INCLUDING THERAPEUTIC ACTIVITY POST-BV FAILURE.ANALYSIS OF TUMOR BIOPSIES SHOWED INCREASED NUMBERS OF NK CELLS BOTH BEFORE AND DURING TREATMENT WITH AFM13 AMONGST THE PATIENTS RESPONDING TO THERAPY.COMBINATION OF AFM13 AND PEMBROLIZUMAB ACHIEVED HIGH AND DEEP RESPONSE RATES EVEN IN PATIENTS WHO WERE REFRACTORY TO BRENTUXIMAB VEDOTIN.

Affimed Announces Research And Development Strategy To Focus On Innate Immunity Portfolio Reports First Quarter 2019 Financial Results And Operational Progress

May 22 (Reuters) - Affimed NV <A28.F>::AFFIMED ANNOUNCES RESEARCH AND DEVELOPMENT STRATEGY TO FOCUS ON INNATE IMMUNITY PORTFOLIO; REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q1 EARNINGS PER SHARE EUR 0.03.Q1 REVENUE EUR 11.4 MILLION VERSUS EUR 500,000.CO TO FOCUS ON DEVELOPMENT OF AFM13, AFM24 AND PRECLINICAL INNATE CELL ENGAGERS, DECIDES TO TERMINATE AFM11 T CELL ENGAGER PHASE 1 PROGRAM.SEES CASH, CASH EQUIVALENTS,SHORT-TERM DEPOSITS AS OF MARCH 31, 2019 TO ENABLE CO TO FUND PLANNED CLINICAL DEVELOPMENT,EARLY DEVELOPMENT ACTIVITIES INTO 2021.

Affimed Reports 2018 Financial Results

March 27 (Reuters) - Affimed NV <A28.F>::AFFIMED REPORTS 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.AFFIMED NV - AFM24: IND SUBMISSION PLANNED FOR MID-2019; PLANS TO INITIATE FIRST-IN-HUMAN STUDY IN SECOND HALF OF 2019.AFFIMED NV - CLINICAL DATA UPDATES FROM MONOTHERAPY STUDY AND COMBINATION STUDY WITH KEYTRUDA (PEMBROLIZUMAB) EXPECTED IN 2019.

Affimed NV Reports Q3 Loss of EUR 0.19 Per Share

Nov 7 (Reuters) - Affimed NV <A28.F>::AFFIMED REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2018 AND OPERATIONAL PROGRESS.Q3 LOSS PER SHARE EUR 0.19.Q3 REVENUE EUR 300,000 VERSUS EUR 500,000.

Affimed N.V Files For Mixed Shelf Of Up To $150 Million

Oct 22 (Reuters) - Affimed NV <A28.F>::AFFIMED N.V FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up